CHMP4C antibody (AA 1-233)

Catalog No. ABIN7147525

Product Details anti-CHMP4C Antibody

Target: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Binding Specificity: AA 1-233

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CHMP4C antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC)

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Charged multivesicular body protein 4c protein (1-233AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for CHMP4C

Target: CHMP4C (Charged Multivesicular Body Protein 4C (CHMP4C))

Alternative Name: CHMP4C (CHMP4C Products)

Synonyms: 2010012P02Rik antibody, 2210015K02Rik antibody, 2310010I16Rik antibody, Shax3 antibody, Snf7-3 antibody, SNF7-3 antibody, VPS32C antibody, zgc:110173 antibody, CHMP4c antibody, chmp4c antibody, charged multivesicular body protein 4C antibody, charged multivesicular body protein 4C L homeolog antibody, Chmp4c antibody, CHMP4C antibody, chmp4c antibody, chmp4c.L antibody

Background:

Background: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). Key component of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage: upon phosphorylation by AURKB, together with ZFYVE19/ANCHR, retains abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ANCHR and VPS4 and subsequent abscission (PubMed:22422861, PubMed:24814515). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release. CHMP4A/B/C are required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413).

Aliases: Charged multivesicular body protein 4c antibody, CHM4C_HUMAN antibody, CHMP4c antibody, Chromatin-modifying protein 4c antibody, hSnf7-3 antibody, hVps32-3 antibody, SHAX3 antibody, SNF7 homolog associated with Alix 3 antibody, SNF7-3 antibody, Vacuolar protein sorting-associated protein 32-3 antibody, Vps32-3 antibody

UniProt: Q96CF2